Tag archive for ‘Xyosted Launch Progress’
Antares Pharma: The Xyosted Launch Looks Like it will Meet or Beat Wall Street Expectations for 2019 (ATRS, Buy, $2.90)
Investment Thesis The cornerstone of my positive investment thesis for Antares is Xyosted, which was fully launched in January 2019. While it is very early, I believe that the prescription trends seen over the last four plus months strongly indicate that the launch will be a success. Xyosted is Antares’ second wholly owned and marketed […]